9-5053743-C-T

Variant summary

Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1

The NM_004972.4(JAK2):​c.615-820C>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.242 in 151,312 control chromosomes in the GnomAD database, including 4,746 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.

Frequency

Genomes: 𝑓 0.24 ( 4746 hom., cov: 32)

Consequence

JAK2
NM_004972.4 intron

Scores

2

Clinical Significance

Not reported in ClinVar

Conservation

PhyloP100: -0.103

Publications

10 publications found
Variant links:
Genes affected
JAK2 (HGNC:6192): (Janus kinase 2) This gene encodes a non-receptor tyrosine kinase that plays a central role in cytokine and growth factor signalling. The primary isoform of this protein has an N-terminal FERM domain that is required for erythropoietin receptor association, an SH2 domain that binds STAT transcription factors, a pseudokinase domain and a C-terminal tyrosine kinase domain. Cytokine binding induces autophosphorylation and activation of this kinase. This kinase then recruits and phosphorylates signal transducer and activator of transcription (STAT) proteins. Growth factors like TGF-beta 1 also induce phosphorylation and activation of this kinase and translocation of downstream STAT proteins to the nucleus where they influence gene transcription. Mutations in this gene are associated with numerous inflammatory diseases and malignancies. This gene is a downstream target of the pleiotropic cytokine IL6 that is produced by B cells, T cells, dendritic cells and macrophages to produce an immune response or inflammation. Disregulation of the IL6/JAK2/STAT3 signalling pathways produces increased cellular proliferation and myeloproliferative neoplasms of hematopoietic stem cells. A nonsynonymous mutation in the pseudokinase domain of this gene disrupts the domains inhibitory effect and results in constitutive tyrosine phosphorylation activity and hypersensitivity to cytokine signalling. This gene and the IL6/JAK2/STAT3 signalling pathway is a therapeutic target for the treatment of excessive inflammatory responses to viral infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020]
INSL6 (HGNC:6089): (insulin like 6) The protein encoded by this gene contains a classical signature of the insulin superfamily and is significantly similar to relaxin and relaxin-like factor. This gene is preferentially expressed in testis. Its expression in testis is restricted to interstitial cells surrounding seminiferous tubules, which suggests a role in sperm development and fertilization. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -12 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.94).
BA1
GnomAd4 highest subpopulation (SAS) allele frequency at 95% confidence interval = 0.293 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
JAK2NM_004972.4 linkc.615-820C>T intron_variant Intron 6 of 24 ENST00000381652.4 NP_004963.1 O60674

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
JAK2ENST00000381652.4 linkc.615-820C>T intron_variant Intron 6 of 24 1 NM_004972.4 ENSP00000371067.4 O60674
JAK2ENST00000636127.1 linkc.615-820C>T intron_variant Intron 6 of 15 5 ENSP00000489812.1 A0A1B0GTR9

Frequencies

GnomAD3 genomes
AF:
0.243
AC:
36667
AN:
151194
Hom.:
4752
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.153
Gnomad AMI
AF:
0.283
Gnomad AMR
AF:
0.280
Gnomad ASJ
AF:
0.255
Gnomad EAS
AF:
0.258
Gnomad SAS
AF:
0.305
Gnomad FIN
AF:
0.331
Gnomad MID
AF:
0.212
Gnomad NFE
AF:
0.268
Gnomad OTH
AF:
0.245
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome
AF:
0.242
AC:
36669
AN:
151312
Hom.:
4746
Cov.:
32
AF XY:
0.247
AC XY:
18221
AN XY:
73854
show subpopulations
African (AFR)
AF:
0.153
AC:
6301
AN:
41280
American (AMR)
AF:
0.280
AC:
4226
AN:
15092
Ashkenazi Jewish (ASJ)
AF:
0.255
AC:
882
AN:
3458
East Asian (EAS)
AF:
0.258
AC:
1331
AN:
5162
South Asian (SAS)
AF:
0.306
AC:
1469
AN:
4796
European-Finnish (FIN)
AF:
0.331
AC:
3465
AN:
10482
Middle Eastern (MID)
AF:
0.190
AC:
56
AN:
294
European-Non Finnish (NFE)
AF:
0.268
AC:
18169
AN:
67732
Other (OTH)
AF:
0.243
AC:
512
AN:
2104
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
1373
2746
4120
5493
6866
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
390
780
1170
1560
1950
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.181
Hom.:
507
Bravo
AF:
0.230
Asia WGS
AF:
0.265
AC:
919
AN:
3478

ClinVar

Not reported in ClinVar

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.94
CADD
Benign
0.87
DANN
Benign
0.92
PhyloP100
-0.10
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs2149555; hg19: chr9-5053743; COSMIC: COSV67594703; API